Prelude Therapeutics Is A Clinical Stage Precision Oncology Company Based In Wilmingtondelawarethe Company Is Dedicated To Developing Innovative Medicines For Cancer Patientsparticularly In Areas With High Unmet Needsprelude Focuses On Creating Transformative Therapies By Leveraging Advancements In Cancer Biology And Technology The Company Specializes In Designing And Developing Novel Small Molecule Compounds That Target Critical Cancer Cell Pathwaystheir Pipeline Includes Several Promising Candidatessuch As Prt3789A First In Class Intravenous Smarca2 Degraderand Prt7732A Preclinical Oral Smarca2 Selective Degraderother Candidates Include Prt2527A Selective Cdk9 Inhibitorprt3645A Next Generation Cdk4 6 Inhibitorand Prt1419A Selective Inhibitor Of Mcl1Prelude Therapeutics Also Collaborates With Abcellera To Develop Next Generation Precision Antibody Drug Conjugates With A Strong Financial Positionprelude Therapeutics Has A Cash Runway Extending Into 2026Allowing It To Advance Its Diverse Pipeline Into Clinical Trialsthe Company Is Committed To Improving The Lives Of Cancer Patients Through Safe And Effective Treatments
No conferences found for this company.
| Company Name | Prelude Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
